

16 November 2023

ASX Announcement

Results of Annual General Meeting

SYDNEY Australia, 16 November 2023: Australian antiviral drug development company, Island Pharmaceuticals Ltd (ASX: ILA; "Island"; "the Company") advises that its Annual General Meeting was held today at 11.30 am AEDT.

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

Resolutions 2, 3, 4 and 6 were passed on a poll, with Resolution 3 (Approval of increased placement capacity) and Resolution 4 (Adoption of new constitution) being passed by a sufficient majority as special resolutions.

Resolution 1 (Adoption of Remuneration Report) received a first strike and Resolution 5 (Adoption of Employee Incentive Plan) was not passed.

Further information required by Listing Rule 3.13.2 and section 251AA(2) of the Corporations Act 2001 (Cth) is set out in the attached voting summary.

Approved for release to the ASX by:

Dr Paul MacLeman
Executive Chairman
Island Pharmaceuticals Ltd
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Jane Lowe
IR Department
Mobile: +61 411 117 774
jane.lowe@irdepartment.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is a drug repurposing company, focused on areas of unmet need for antiviral therapeutics to address infectious diseases. Our lead asset is ISLA-101, a drug with a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases.

If ISLA-101 achieves FDA approval, and certain other criteria are met, Island may be eligible to obtain a "Priority Review Voucher" at the time of FDA approval. This means that as well as getting approval to manufacture and sell ISLA-101, the Priority Review Voucher (PRV) could permit Island to expedite the FDA approval process for a new drug or sell the PRV in a secondary market.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.

Disclosure of Proxy Votes

Island Pharmaceuticals Limited

Annual General Meeting

Thursday, 16 November 2023



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 Adoption of Remuneration Report	P	14,162,172	14,159,231 99.98%	2,941 0.02%	0	0 0.00%	1,357,458 9.59%	12,804,714 90.41%	0	-
2 Re-election of David Brookes	P	19,411,001	19,411,001 100.00%	0 0.00%	0	0 0.00%	19,411,001 100.00%	0 0.00%	0	Passed
3 Approval of increased placement capacity	P	19,411,001	19,140,001 98.60%	271,000 1.40%	0	0 0.00%	19,140,001 98.60%	271,000 1.40%	0	Passed
4 Adoption of new constitution	P	19,411,001	19,411,001 100.00%	0 0.00%	0	0 0.00%	19,411,001 100.00%	0 0.00%	0	Passed
5 Adoption of new Employee Incentive Plan	P	14,050,172	14,050,172 100.00%	0 0.00%	0	0 0.00%	1,248,399 100.00%	0 0.00%	12,801,773	Passed
6 Appointment of Auditor	P	19,411,001	19,411,001 100.00%	0 0.00%	0	0 0.00%	19,411,001 100.00%	0 0.00%	0	Passed

